Profile: Flamel Technologies SA (FLML.O)
14 Mar 2014
Flamel Technologies SA, incorporated on August 10, 1990, has a pipeline of niche specialty pharmaceutical products. The Company’s drug delivery platforms are focused on developing safer, more efficacious formulations of drugs to address unmet medical needs. Its pipeline includes biological and chemical drugs formulated with its Medusa and Micropump (and its applications to the development of liquid formulations, which is LiquiTime and of abuse-deterrent formulations Trigger Lock) drug delivery platforms. It has collaborations with a number of pharmaceutical and biotechnology companies, including GlaxoSmithKline (Coreg CR, carvedilol phosphate). Its Medusa is based on a hydrophilic biodegradable polyglutamate chain grafted with hydrophobic Vitamin E.
The Company’s LiquiTime allows the development of oral controlled release liquid formulations of drugs for patients who have difficulty swallowing tablets or capsules, such as children and the elderly. Its Micropump is designed for the extended (and/or delayed) release of small chemical drugs via oral administration. It may be used to develop extremely precise pharmacokinetic profiles of single or combination of drugs, in a variety of formats (pill, tablet, capsule, sachet, or liquid). Its DeliVax improves immunological response by increasing antigen persistence in vivo and modifying antigen presentation to competent cell.
Flamel Technologies SA
33, avenue du Dr. Georges Levy,
Venissieux Cedex, PARC CLUB DU M